{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:38:24Z","timestamp":1787027904482,"version":"build-2736575974"},"reference-count":31,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"crossref","award":["19VAL001"],"award-info":[{"award-number":["19VAL001"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Human epidermal growth factor receptor 2 (HER2) is a molecular target of interest in prostate cancer due to its association with poor prognosis and its potential role in androgen receptor signaling. However, earlier clinical trials investigating HER2-targeted therapies, including antibodies and small molecules, have shown limited efficacy. More recent studies using the HER2 antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) suggest potential therapeutic benefit in prostate cancer. However, its effective utilization requires a HER2 IHC scoring system that accurately represents HER2 expression patterns unique to prostate cancer, which is currently not established. We have developed a modified HER2 IHC scoring system that, unlike the breast and gastrointestinal tumor HER2 IHC grading scales, considers the distinct spatiotemporal expression of HER2 in prostate tumors. In this commentary, we discussed two patients with metastatic prostate cancer who were classified as HER2 IHC 3+ using our prostate cancer-specific scoring system and who demonstrated meaningful clinical responses and responded to treatment with T-DXd. We further review the historical evolution of HER2 testing in prostate cancer, as well as factors that may have contributed to the failure of previous clinical trials targeting HER2 in prostate tumors. Our aim is to highlight the need for developing a standardized HER2 IHC grading model in prostate cancer, which could improve the predictive value of HER2 IHC expression, enabling a more accurate identification of patients likely to benefit from HER2-targeted ADCs.<\/jats:p>","DOI":"10.3390\/curroncol33020091","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T10:48:01Z","timestamp":1770115681000},"page":"91","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Historical Perspective of HER2 Testing and Treatment in Prostate Cancer"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7681-9052","authenticated-orcid":false,"given":"Natalia","family":"Zamalloa","sequence":"first","affiliation":[{"name":"Department of Pathology, George Washington University, Washington, DC 20037, USA"},{"name":"Department of Pathology and Laboratory Medical Service, Veterans Affairs Medical Center, Washington, DC 20422, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Rose","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, George Washington University, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coen J.","family":"Lap","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Edward P. Evans Precision Oncology Center of Excellence, Veterans Affairs Medical Center, Washington, DC 20422, USA"},{"name":"Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-176X","authenticated-orcid":false,"given":"Rithika","family":"Rajendran","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Edward P. Evans Precision Oncology Center of Excellence, Veterans Affairs Medical Center, Washington, DC 20422, USA"},{"name":"Department of Internal Medicine, Capital Health Regional Medical Center, Trenton, NJ 08638, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8141-7770","authenticated-orcid":false,"given":"Fayez","family":"Estephan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, George Washington University, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Jatwani","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, George Washington University, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarati","family":"Poudel","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Edward P. Evans Precision Oncology Center of Excellence, Veterans Affairs Medical Center, Washington, DC 20422, USA"},{"name":"Department of Hematology and Oncology, George Washington University, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Subrahmanyam","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Edward P. Evans Precision Oncology Center of Excellence, Veterans Affairs Medical Center, Washington, DC 20422, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula J.","family":"Hurley","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1438-9665","authenticated-orcid":false,"given":"Victor E.","family":"Nava","sequence":"additional","affiliation":[{"name":"Department of Pathology, George Washington University, Washington, DC 20037, USA"},{"name":"Department of Pathology and Laboratory Medical Service, Veterans Affairs Medical Center, Washington, DC 20422, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4394-3055","authenticated-orcid":false,"given":"Maneesh","family":"Jain","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Edward P. Evans Precision Oncology Center of Excellence, Veterans Affairs Medical Center, Washington, DC 20422, USA"},{"name":"Department of Hematology and Oncology, George Washington University, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"ref_1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ccr.2004.09.031","article-title":"HER2\/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability","volume":"6","author":"Mellinghoff","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15221","DOI":"10.1016\/j.anndiagpath.2023.152219","article-title":"The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma","volume":"67","author":"Estephan","year":"2023","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/mc.2940050413","article-title":"Expression of c-erb B-2\/neu proto-oncogene in human prostatic cancer tissues and cell lines","volume":"5","author":"Zhau","year":"1992","journal-title":"Mol. Carcinog."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0046-8177(97)90157-X","article-title":"HER-2\/neu gene amplification status in prostate cancer by fluorescence in situ hybridization","volume":"28","author":"Ross","year":"1997","journal-title":"Hum. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-09-2546","article-title":"Low-level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer","volume":"16","author":"Minner","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/jnci\/92.23.1918","article-title":"HER2\/neu expression and progression toward androgen independence in human prostate cancer","volume":"92","author":"Signoretti","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/15384047.2018.1523849","article-title":"Next-generation sequencing of prostate cancer: Genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing","volume":"20","author":"Ikeda","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17588359221112822","DOI":"10.1177\/17588359221112822","article-title":"Next-generation sequencing, should I use anti-HER2 therapy for HER2-amplified tumors off-label? Illustrating an extrapolation framework","volume":"14","author":"Cho","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/pros.20065","article-title":"The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial","volume":"60","author":"Ziada","year":"2004","journal-title":"Prostate"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.10339","article-title":"HER-2 profiling and targeting in prostate carcinoma: A Phase II trial of trastuzumab alone and with paclitaxel","volume":"94","author":"Morris","year":"2002","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/cncr.20228","article-title":"Trastuzumab plus docetaxel in HER2\/neu-positive prostate carcinoma: Final results from the California Cancer Consortium screening and phase II trial","volume":"100","author":"Lara","year":"2004","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2006.07.0649","article-title":"Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy","volume":"25","author":"Agus","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.2006.07.0888","article-title":"Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer","volume":"25","author":"Bellmunt","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/COC.0b013e3181beac33","article-title":"A multicenter phase II clinical trial of lapatinib in hormonally untreated advanced prostate cancer","volume":"33","author":"Sridhar","year":"2010","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.urolonc.2010.09.018","article-title":"A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer","volume":"31","author":"Whang","year":"2013","journal-title":"Urol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Indini, A., Rijavec, E., and Grossi, F. (2021). Trastuzumab deruxtecan: Changing the destiny of HER2-expressing solid tumors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094774"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_21","first-page":"e187151","article-title":"Identification of asporin as a HER3 ligand exposes a therapeutic vulnerability in prostate cancer","volume":"10","author":"Hesterberg","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_22","first-page":"2643","article-title":"HER2\/neu (p185neu) protein expression in the natural or treated history of prostate cancer","volume":"7","author":"Osman","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.3748\/wjg.v22.i19.4619","article-title":"HER2 testing in gastric cancer: An update","volume":"22","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0022-5347(05)64462-X","article-title":"Her2 expression in prostatic cancer: A comparison with mammary carcinoma","volume":"168","author":"Jorda","year":"2002","journal-title":"J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1158\/2767-9764.CRC-25-0069","article-title":"Patterns of HER2 expression in metastatic prostate and urothelial cancers: Implications for HER2-targeted therapies","volume":"5","author":"Lee","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: Guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.3748\/wjg.v19.i38.6438","article-title":"HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays","volume":"19","author":"Wohnrath","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ma, X., Zhou, L., Wu, Q., Jia, L., Diao, X., Kang, Q., Huang, X., Liu, Y., Hu, T., and Long, M. (2023). Loss of human epidermal receptor 2 expression in formalin-fixed paraffin-embedded breast cancer samples and the rescuing effect of enhanced antigen retrieval and signal amplification. Life, 14.","DOI":"10.3390\/life14010031"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.humpath.2006.04.004","article-title":"HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: Comparison with clinically detected androgen-dependent and androgen-independent cancer","volume":"37","author":"Montironi","year":"2006","journal-title":"Hum. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.7326\/ANNALS-24-01409","article-title":"Response of human epidermal growth factor receptor 2\u2013expressing prostate cancer to trastuzumab deruxtecan","volume":"177","author":"Lap","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"oyaf207","DOI":"10.1093\/oncolo\/oyaf207","article-title":"Clinical response to novel combination of trastuzumab deruxtecan and abiraterone in HER2-expressing metastatic castration-resistant prostate cancer","volume":"30","author":"Rajendran","year":"2025","journal-title":"Oncologist"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/91\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:16:01Z","timestamp":1770182161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/91"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["curroncol33020091"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33020091","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}